Theravance Biopharma, Inc. (the "Company") is announcing that it has voluntarily discontinued its Phase 2 study of izencitinib (gut-selective oral pan-JAK inhibitor for inflammatory intestinal diseases) in Crohn's disease (Study 0173). The Company's decision was made following the planned review of trial data by the independent data monitoring committee who determined that, while there are no safety concerns, there are concerns about the ongoing benefit-risk of continuing the trial, and the committee recommended the sponsor discontinue the study. The Company has made the decision to discontinue the study.
https://www.marketscreener.com/quote/stock/THERAVANCE-BIOPHARMA-INC-16501278/news/THERAVANCE-BIOPHARMA-INC-Other-Events-form-8-K-37038943/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.